FindTrial
Sign In

A study to compare two types of chemotherapy that is 3 plus 7 & AZA plus VEN for the treatment of a blood cancer called Acute Myeloid Leukemia

A single centre prospective observational study to compare the outcomes & toxicities of Azacitidine plus Venetoclax (AZA plus VEN) with 3 plus 7 induction chemotherapy (IC) with Cytarabine and Daunorubicin in patients with Acute Myeloid Leukemia (AML)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/06/053981
Enrollment
200
Registered
2023-06-16
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C929- Myeloid leukemia, unspecified

Interventions

Intervention1: Not Applicable: Not Applicable

Sponsors

Dr Manju Sengar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1- Newly diagnosed patients with Acute Myeloid Leukemia (AML) of any risk group, 18 years of age or older 2- No prior therapy 3- Willing to continue treatment (induction) at TMH

Exclusion criteria

Exclusion criteria: 1- Acute Promyelocytic Leukemia 2- Patients not willing to participate in the study

Design outcomes

Primary

MeasureTime frame
Induction related mortalityTimepoint: End of Induction that is 28 to 35 days—

Secondary

MeasureTime frame
Complete Remission RateTimepoint: End of Induction that is 28 to 35 days;Quality of LifeTimepoint: End of Induction that is 28 to 35 days;Cost of treatmentTimepoint: End of Induction that is 28 to 35 days;Time toxicity that is the number of days the patient is in contact with healthcareTimepoint: End of Induction that is 28 to 35 days—

Countries

India

Contacts

Public ContactDr Arvind Vaidyanathan

Tata Memorial Hospital

manju.sengar@gmail.com9769690590

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026